Advanced search
Publication Cover
Clinical Toxicology Volume 60, 2022 - Issue 4
Submit an article Journal homepage
1,950
Views
4
CrossRef citations to date
0
Altmetric
Clinical Research

Clinical experience with titrating doses of digoxin antibodies in acute digoxin poisoning. (ATOM-6)

Betty S. Chana Clinical Toxicology Unit & Emergency Department, Prince of Wales Hospital, Sydney, New South Wales, Australia;b New South Wales Poisons Information Centre, Sydney, AustraliaCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0003-0083-282XView further author information
ORCID Icon,
Geoffrey K. Isbisterb New South Wales Poisons Information Centre, Sydney, Australia;c Clinical Toxicology Research Group, University of Newcastle, Newcastle, Australia;d Department of Clinical Toxicology, Calvary Mater Newcastle, Newcastle, AustraliaORCID Iconhttps://orcid.org/0000-0003-1519-7419View further author information
ORCID Icon,
Angela Chiewa Clinical Toxicology Unit & Emergency Department, Prince of Wales Hospital, Sydney, New South Wales, Australia;b New South Wales Poisons Information Centre, Sydney, AustraliaORCID Iconhttps://orcid.org/0000-0002-0079-5056View further author information
ORCID Icon,
Katherine Isoardie Clinical Toxicology Unit, Princess Alexandra Hospital, Brisbane, Australia;f Queensland Poisons Information Centre, Brisbane, AustraliaORCID Iconhttps://orcid.org/0000-0002-1176-7923View further author information
ORCID Icon &
Nicholas A. Buckleyb New South Wales Poisons Information Centre, Sydney, Australia;g Faculty of Medicine and Health, University of Sydney, Sydney, AustraliaORCID Iconhttps://orcid.org/0000-0002-6326-4711View further author information
ORCID Icon
Pages 433-439 | Received 25 Jun 2021, Accepted 09 Aug 2021, Published online: 23 Aug 2021

References

  • Chhabra N, Valento M, Bryant SM, et al. Digoxin-specific antibody fragment dosing: a case series. Am J Ther. 2016;23(6):e1597–e1601.
  • Antman EM, Wenger TL, Butler VP, Jr, et al. Treatment of 150 cases of life-threatening digitalis intoxication with digoxin-specific fab antibody fragments. Final report of a multicenter study. Circulation. 1990;81(6):1744–1752.
  • Hickey AR, Wenger TL, Carpenter VP, et al. Digoxin immune fab therapy in the management of digitalis intoxication: safety and efficacy results of an observational surveillance study. J Am Coll Cardiol. 1991;17(3):590–598.
  • Smolarz A, Roesch E, Lenz E, et al. Digoxin specific antibody (fab) fragments in 34 cases of severe digitalis intoxication. J Toxicol Clin Toxicol. 1985;23(4–6):327–340.
  • Chan BS, Isbister GK, O'Leary M, et al. Efficacy and effectiveness of anti-digoxin antibodies in chronic digoxin poisonings from the DORA study (ATOM-1). Clin Toxicol. 2016;54(6):488–494.
  • Chan BS, Isbister GK, Page CB, et al. Clinical outcomes from early use of digoxin-specific antibodies versus observation in chronic digoxin poisoning (ATOM-4). Clin Toxicol. 2019;57(7):638–643.
  • Bracken LM, Chan BSH, Buckley NA. Physiologically based pharmacokinetic modelling of acute digoxin toxicity and the effect of digoxin-specific antibody fragments. Clin Toxicol. 2019;57(2):117–124.
  • Bateman DN. Digoxin-specific antibody fragments: how much and when? Toxicol Rev. 2004;23(3):135–143.
  • Lapostolle F, Borron SW, Verdier C, et al. Assessment of digoxin antibody use in patients with elevated serum digoxin following chronic or acute exposure. Intensive Care Med. 2008;34(8):1448–1453.
  • Nordt SP, Clark RF, Machado C, et al. Assessment of digoxin-specific fab fragment dosages in digoxin poisoning. Am J Ther. 2016;23(1):e63–e67.
  • Chan BS, Buckley NA. Digoxin-specific antibody fragments in the treatment of digoxin toxicity. Clin Toxicol. 2014;52(8):824–836.
  • Electronic Resources: Australian Bureau of Statistics. 4364.0–National health survey: summary of results, 2007–2008 (Reissue). 2009. [cited 16 Aug 2021]. Available at: https://www.abs.gov.au/ausstats/[email protected]/mf/4364.
  • Kulawickrama S, O'Leary MA, Hodgson WC, et al. Development of a sensitive enzyme immunoassay for measuring taipan venom in serum. Toxicon. 2010;55(8):1510–1518.
  • Hornestam B, Jerling M, Karlsson MO, DAAf Trial Group. Intravenously Intravenously administered digoxin in patients with acute atrial fibrillation: a population pharmacokinetic/pharmacodynamic analysis based on the digitalis in acute atrial fibrillation trial . Eur J Clin Pharmacol. 2003;58(11):747–755.
  • Bilbault P, Oubaassine R, Rahmani H, et al. Emergency step-by-step specific immunotherapy in severe digoxin poisoning: an observational cohort study. Eur J Emer Med. 2009;16:145–149.
  • Cano NJ, Sabouraud AE, Debray M, et al. Dose-dependent reversal of digoxin-inhibited activity of an in vitro Na + K+ATPase model by digoxin-specific antibody. Toxicol Lett. 1996;85(2):107–111.
  • Spiegel A, Marchlinski FE. Time course for reversal of digoxin toxicity with digoxin-specific antibody fragments. Am Heart J. 1985;109(6):1397–1399.
  • Ujhelyi MR, Robert S. Pharmacokinetic aspects of digoxin-specific fab therapy in the management of digitalis toxicity. Clin Pharmacokinet. 1995;28(6):483–493.
  • Ujhelyi MR, Robert S, Cummings DM, et al. Influence of digoxin immune fab therapy and renal dysfunction on the disposition of total and free digoxin. Ann Intern Med. 1993;119(4):273–277.
  • Chen JY, Liu PY, Chen JH, et al. Safety of transvenous temporary cardiac pacing in patients with accidental digoxin overdose and symptomatic bradycardia. Cardiology. 2004;102(3):152–155.
  • Dart RC, Goldfrank LR, Erstad BL, et al. Expert consensus guidelines for stocking of antidotes in hospitals that provide emergency care. Ann Emerg Med. 2018;71(3):314–325 e1.
  • Electronic Resources: Life Saving Drugs Registers - Antidotes (Digoxin-Specific Antibody Injection). New South Wales Therapeutic Advisory Group Inc. [cited 16 Aug 2021]. Available at: https://www.nswtag.org.au/life-saving-drugs-register/.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.